Automation software company UiPath (NYSE:PATH) will be announcing earnings results this Wednesday after the bell. Here’s what to look for. UiPath beat analysts’ revenue expectations by 4.1% last ...

A new proof-of-concept attack shows that malicious Model Context Protocol servers can inject JavaScript into Cursor’s browser — and potentially leverage the IDE’s privileges to perform system tasks.

The U.S. Federal Reserve (Fed) pumped $29.4 billion into the banking system on Friday, sparking optimism on crypto social media. While the move aimed at easing liquidity concerns and is supportive of ...

Amazon released a new Agentic AI platform. UiPath has made agentic AI automation a central focus. The company also announced several new partnerships last week. The software and automation company's ...

UiPath stock rallied after announcing several new partnerships. The company is looking to reinvent itself as an agentic automation company. The stock is cheap and could have nice upside if these ...

UiPath Inc. has announced major partnerships with AI infrastructure leaders, positioning itself as a key bridge for enterprise AI monetization. PATH's new products and collaborations with Nvidia, ...

In late September 2025, UiPath announced a series of collaborations with leading technology firms, including NVIDIA, OpenAI, Google, Microsoft, and Snowflake, introducing advanced AI capabilities and ...

UiPath agreed to a partnership with OpenAI to simplify and advance AI agent development for business. The agentic automation company said in collaboration with OpenAI, it would build a ChatGPT ...

NEW YORK--(BUSINESS WIRE)--UiPath (NYSE: PATH), a global leader in agentic automation, today announced its positioning as a Leader in the inaugural Gartner ® Magic Quadrant™ for Intelligent Document ...

UiPath Inc. raised its full-year revenue outlook after cruising past Wall Street’s expectations and swinging to a profit in its latest quarterly results, powered by momentum in its artificial ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures ...